The latest news from academia, regulators
research labs and other things of interest
Posted: September 21, 2007
Nanomedicine journal wins prestigious award and is accepted for coverage in MEDLINE
(Nanowerk News) Future Medicine Ltd announced that its journal Nanomedicine (ISSN: 1743-5889) has won the Highly Commended award in the ALPSP Best New Journal category. This follows on from the news that Nanomedicine has also been selected for coverage in MEDLINE.
Earlier this year Nanomedicine was also accepted for coverage in ISI® services after the publication of only five issues.
The ALPSP judging panel cited several reasons for the award including; 'a response to the development of a new scientific community', 'increased use of tables and illustrations', 'a strong in-house editorial team' and 'good links with authors'.
Professor Kostas Kostarelos, Chair in Nanomedicine and Deputy Head, Centre for Drug Delivery Research, University of London (UK) and Senior Editor of the journal added; ' We are delighted that Nanomedicine has been recognized by ALPSP for this prestigious award. This is an extra boost that we were not expecting and completes an excellent year for the journal. The recent listing of Nanomedicine in Medline/PubMed also means that it has been recognized by all of the major bibliographic search engines. The consistency, richness and top-quality content of Nanomedicine along with the great visibility already achieved will make this journal the top reference source for this exciting and exponentially growing field.'
Professor Charles R Martin, Director of the Center for Research at the Bio/Nano Interface and Colonel Allen R and Margaret G Crow Professor of Chemistry, University of Florida (FL, USA), and also Senior Editor of the journal commented; "Nanomedicine's early acceptance by Medline/PubMed is a testament to the importance of this rapidly evolving new field and to the fact that Nanomedicine has quickly become the voice of this research frontier."
Topics covered in the first year of publication by Nanomedicine include basic research and theoretical applications of nanomedical technology, potential medical applications and therapeutic applications of nanotechnology advances, nanomedical tools in gene therapy, drug delivery and commercialization, funding, economics and ethics of nanomedical technology.
Morag Robertson, Editor at Future Medicine said; "The commendation by ALPSP and the acceptance by MEDLINE is tribute to the hard work of our Senior Editors and Editorial Board. The field of nanotechnology and its medical applications has become one of the hottest areas in science today and the launch of Nanomedicine has been greeted with huge interest. I would like to thank everyone who has worked on Nanomedicine as it takes another few steps in becoming the premier forum in this exciting field."
Access to Nanomedicine is also currently available via a free 30-day trial. To apply for your free trial please email firstname.lastname@example.org quoting reference NMMMED and you will be sent email and password access.
About future science group
Future Science Group Ltd, based in London has developed an innovative publishing portfolio to reflect post-genomic medicine. The sequencing of the human genome was a colossal milestone in the evolution of healthcare, with repercussions for all those involved in the healthcare chain. Through its imprints, Future Medicine, Future Drugs and Future Biology, the Future Science Group provides healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in the light of these advances. Our flagship title Pharmacogenomics has evolved to become a leading source of commentary and analysis from international opinion leaders. Momentum toward an individualized approach to medicine is increasing as the value of linking diagnostic and therapeutic approaches becomes ever clearer. For more information please access http://www.future-drugs.com, http://www.futuremedicine.com and http://www.future-biology.com.
Maintained by the U.S. National Library of Medicine®, MEDLINE (Medical Literature Analysis and Retrieval System Online) is a premier bibliographic database containing approximately 13 million references to journal articles in life sciences. The National Library of Medicine MEDLINE selection process is managed by an advisory committee, the Literature Selection Technical Review Committee, composed of authorities knowledgeable in the field of biomedicine, such as physicians, researchers, educators, editors, health science librarians and historians, to review and recommend the journal titles NLM should index. MEDLINE is searchable for free using PubMed at http://pubmed.gov.
ALPSP is the international trade association for nonprofit publishers and those who work with them. ALPSP was formed in 1972 - today it is the only international trade association representing all types of nonprofit publishers, as well as the largest trade association for scholarly and professional publishers. It has 350 members in 36 countries, publishing over 10,000 journals as well as books, databases and other products and services.